US Trastuzumab Competition Heats Up

Mylan And Biocon’s Ogivri Biosimilar Leads New Wave Of Herceptin Rivals

 
• By David Wallace
  
Horse racing
Mylan and Biocon follow Amgen into the biosimilar trastuzumab market, with other firms close behind • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products